Orion stock slips 1.78 percent as buybacks continue

Published on 09/24/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orion stock reported Q2 2026 revenue of EUR 521.60 million against a EUR 505.29 million estimate. Earnings per share reached EUR 1.00 versus EUR 0.96 expected.

Isometrische Grafik der Pharma-Produktionskette, Orion Oyj FI0009014377 — Isometrische 3D-Illustration zeigt Wertschöpfungskette der Pharmaproduktion von Orion Oyj, ISIN FI0009014377, schematisch, Illustration mit AI erstellt.

Orion stock (ISIN FI0009014377) fell 1.78 percent to EUR 82.60 on Nasdaq Helsinki on September 23, 2026. The move came as Orion continued a share buyback program that acquired 107,674 Class B shares during the week ended September 18.

Buyback reaches EUR 8.67 million

According to GlobeNewswire, Orion bought 107,674 shares at an average EUR 80.4870 during week 38, spending EUR 8,666,359.16. The purchases formed part of a program announced on August 27, 2026, running from September 1 through December 31, 2026.

The company held 616,646 treasury shares after the transactions, all Class B shares. The buyback average was EUR 2.113 below the September 23 closing price, a 2.56 percent difference that places the recent purchases below the latest market level.

Q2 revenue beats estimate

Orion's operating performance provides a second reference point. TradingView reports Q2 2026 revenue of EUR 521.60 million against an estimate of EUR 505.29 million. The EUR 16.31 million gap equals 3.23 percent above consensus.

Q2 2026 earnings per share reached EUR 1.00 versus an EUR 0.96 estimate, a 4.17 percent premium. The combination of a revenue beat and a share price 1.78 percent lower in the latest completed session leaves the buyback and valuation response as the key market signals.

Orion stock closes at EUR 82.60

Orion stock stood at EUR 82.60 on Nasdaq Helsinki on September 23, 2026, with the daily change at negative 1.78 percent. Orion describes its strategy as centered on innovative medicines and a diversified portfolio, while its business spans human and veterinary pharmaceuticals and active pharmaceutical ingredients, according to its investor page.